Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2A type 1-C (H2AC6) is a core component of the nucleosome, the fundamental structural unit of chromatin in eukaryotic cells[1][2]. Two molecules of each core histone (H2A, H2B, H3, H4), including H2A type 1-C, assemble into an octamer which DNA wraps around to form nucleosomes, facilitating chromatin compaction and regulating DNA accessibility for key processes such as transcription, DNA replication, and DNA repair[1][2]. H2AC6 is a replication-dependent, intronless gene expressed during S-phase, and its mRNA lacks a polyA tail but features a unique stem-loop 3’ end[1][2]. Mutations in H2AC6 have been linked to neurodevelopmental disorders with features such as developmental delay, epilepsy, and cerebellar atrophy[3]. It is not established as a therapeutic target or druggable protein, but perturbations in its function or structure can have significant consequences for chromatin architecture and genome stability[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2A type 1-C (H2AC6).